-
Je něco špatně v tomto záznamu ?
Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
K. Cervena, P. Vodicka, V. Vymetalkova,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, systematický přehled
Grantová podpora
NV17-30920A
MZ0
CEP - Centrální evidence projektů
- MeSH
- lidé MeSH
- nádorové biomarkery genetika MeSH
- nádory diagnóza genetika patologie MeSH
- prognóza MeSH
- tekutá biopsie metody MeSH
- volné cirkulující nukleové kyseliny genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- systematický přehled MeSH
The development of minimally invasive and low-cost assay enabling early diagnosis, treatment response and prognosis in cancer patients may provide a promising alternative to tumor biopsy. Circulating cell-free DNA (cfDNA) is probably the most promising tool among all components of liquid biopsy. This review includes studies exploring cfDNA as the diagnostic, prognostic or predictive biomarker for all types of cancer. In this article, we systematically reviewed the relevant literature from PubMed about cfDNA. All articles presented higher cfDNA concentration in cancer patients when compared with patients with benign disease or healthy individuals. Most of the articles showed a connection between cfDNA and prognosis. The presence of high cfDNA level in serum or plasma was associated with worse overall patient's survival. This review supports the idea that the cfDNA analysis represents a promising research area and hopefully in the future, could be applied as a new biomarker for cancer detection, prognosis determination and prediction of the response to therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006035
- 003
- CZ-PrNML
- 005
- 20200518132256.0
- 007
- ta
- 008
- 200511s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.mrrev.2019.05.002 $2 doi
- 035 __
- $a (PubMed)31416571
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Cervena, Klara $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Albertov 4, Charles University, 12800 Prague, Czech Republic. Electronic address: klara.cervena@iem.cas.cz.
- 245 10
- $a Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review / $c K. Cervena, P. Vodicka, V. Vymetalkova,
- 520 9_
- $a The development of minimally invasive and low-cost assay enabling early diagnosis, treatment response and prognosis in cancer patients may provide a promising alternative to tumor biopsy. Circulating cell-free DNA (cfDNA) is probably the most promising tool among all components of liquid biopsy. This review includes studies exploring cfDNA as the diagnostic, prognostic or predictive biomarker for all types of cancer. In this article, we systematically reviewed the relevant literature from PubMed about cfDNA. All articles presented higher cfDNA concentration in cancer patients when compared with patients with benign disease or healthy individuals. Most of the articles showed a connection between cfDNA and prognosis. The presence of high cfDNA level in serum or plasma was associated with worse overall patient's survival. This review supports the idea that the cfDNA analysis represents a promising research area and hopefully in the future, could be applied as a new biomarker for cancer detection, prognosis determination and prediction of the response to therapy.
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a volné cirkulující nukleové kyseliny $x genetika $7 D000073888
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a tekutá biopsie $x metody $7 D000073890
- 650 _2
- $a nádory $x diagnóza $x genetika $x patologie $7 D009369
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Albertov 4, Charles University, 12800 Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic.
- 700 1_
- $a Vymetalkova, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Albertov 4, Charles University, 12800 Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic.
- 773 0_
- $w MED00003430 $t Mutation research $x 1873-135X $g Roč. 781, č. - (2019), s. 100-129
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31416571 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200518132256 $b ABA008
- 999 __
- $a ok $b bmc $g 1524893 $s 1096091
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 781 $c - $d 100-129 $e 20190511 $i 1873-135X $m Mutation research $n Mutat Res $x MED00003430
- GRA __
- $a NV17-30920A $p MZ0
- LZP __
- $a Pubmed-20200511
